Maria Wilkerson
Family · Magnolia, ARNPI 1427090372
Payments from drug & device makers
Across 153 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$381
- Takeda Pharmaceuticals U.S.A., Inc.$285
- Pfizer$241
- Novo Nordisk$207
- Lilly USA, LLC$174
- Novartis$142
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,808100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $381 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $285 |
| Pfizer | 17 | $241 |
| Novo Nordisk | 8 | $207 |
| Lilly USA, LLC | 12 | $174 |
| Novartis | 10 | $142 |
| Esperion Therapeutics, Inc. | 3 | $142 |
| Astellas Pharma US Inc | 2 | $128 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| GSK | 6 | $124 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $97 |
| Bayer | 6 | $89 |
| Alkermes, Inc. | 1 | $79 |
| Exact Sciences | 4 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Merck | 3 | $54 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Amgen | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $48 |
| Boehringer Ingelheim | 2 | $34 |
| AstraZeneca | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Dexcom, Inc. | 2 | $28 |
| Abbott | 1 | $23 |
| Mylan Specialty L.p. | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,817 in reported general payments places this provider in the 85th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 87 | $77,027 |
| OzempicSemaglutide | 79 | $71,099 |
| MounjaroTirzepatide | 36 | $38,985 |
| FarxigaDapagliflozin Propanediol | 42 | $30,977 |
| EliquisApixaban | 36 | $29,500 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $29,302 |
| TrulicityDulaglutide | 16 | $15,729 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $13,652 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $9,066 |
| TrintellixVortioxetine Hydrobromide | 11 | $4,931 |
| VascepaIcosapent Ethyl | 13 | $4,497 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $3,456 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,168 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 112 | $2,758 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 13 | $2,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $34 | $77,02787 claims |
| Novo NordiskOzempic | $207 | $71,09979 claims |
| Lilly USA, LLCMounjaro, Trulicity | $174 | $54,71452 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $28 | $47,79776 claims |
| PfizerEliquis | $241 | $29,50036 claims |
| GSKTrelegy Ellipta | $124 | $29,30242 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $285 | $4,93111 claims |
| AbbVieSynthroid | $381 | $1,41418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,103 family providers in Arkansas.
Other family in Magnolia
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.